Hummel Kevin, Whittaker Sarah, Sillett Nick, Basken Amy, Berghammer Malin, Chalela Tomás, Chauhan Julie, Garcia Luis Antonio, Hasan Babar, Jenkins Kathy, Ladak Laila Akbar, Madsen Nicolas, March Almudena, Pearson Disty, Schwartz Steven M, St Louis James D, van Beynum Ingrid, Verstappen Amy, Williams Roberta, Zheleva Bistra, Hom Lisa, Martin Gerard R
Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Department of Pediatric Cardiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, USA.
Eur Heart J Qual Care Clin Outcomes. 2021 Jul 21;7(4):354-365. doi: 10.1093/ehjqcco/qcab009.
Congenital heart disease (CHD) is the most common congenital malformation. Despite the worldwide burden to patient wellbeing and health system resource utilization, tracking of long-term outcomes is lacking, limiting the delivery and measurement of high-value care. To begin transitioning to value-based healthcare in CHD, the International Consortium for Health Outcomes Measurement aligned an international collaborative of CHD experts, patient representatives, and other stakeholders to construct a standard set of outcomes and risk-adjustment variables that are meaningful to patients.
The primary aim was to identify a minimum standard set of outcomes to be used by health systems worldwide. The methodological process included four key steps: (i) develop a working group representative of all CHD stakeholders; (ii) conduct extensive literature reviews to identify scope, outcomes of interest, tools used to measure outcomes, and case-mix adjustment variables; (iii) create the outcome set using a series of multi-round Delphi processes; and (iv) disseminate set worldwide. The Working Group established a 15-item outcome set, incorporating physical, mental, social, and overall health outcomes accompanied by tools for measurement and case-mix adjustment variables. Patients with any CHD diagnoses of all ages are included. Following an open review process, over 80% of patients and providers surveyed agreed with the set in its final form.
This is the first international development of a stakeholder-informed standard set of outcomes for CHD. It can serve as a first step for a lifespan outcomes measurement approach to guide benchmarking and improvement among health systems.
先天性心脏病(CHD)是最常见的先天性畸形。尽管对患者健康和卫生系统资源利用造成了全球负担,但缺乏对长期结局的跟踪,这限制了高价值医疗的提供和衡量。为了开始向基于价值的先天性心脏病医疗过渡,国际健康结局测量联盟联合了先天性心脏病专家、患者代表和其他利益相关者的国际合作团队,构建一套对患者有意义的标准结局和风险调整变量。
主要目的是确定一套全球卫生系统都可使用的最低标准结局集。方法过程包括四个关键步骤:(i)组建一个代表所有先天性心脏病利益相关者的工作组;(ii)进行广泛的文献综述,以确定范围、感兴趣的结局、用于测量结局的工具以及病例组合调整变量;(iii)通过一系列多轮德尔菲法创建结局集;(iv)在全球范围内传播该结局集。工作组制定了一个包含15项内容的结局集,纳入了身体、心理、社会和整体健康结局,并配有测量工具和病例组合调整变量。纳入所有年龄段任何先天性心脏病诊断的患者。经过公开评审过程,超过80%接受调查的患者和提供者同意最终形式的结局集。
这是首次由利益相关者参与制定的先天性心脏病标准结局集的国际成果。它可作为寿命结局测量方法的第一步,以指导卫生系统之间的基准比较和改进。